Search
Arsanilic acid
go.drugbank.com/drugs/DB03006ExperimentalVet approvedAn arsenical which has been used as a feed additive for enteric conditions in pigs and poultry. It causes blindness and is ototoxic and nephrotoxic in animals. [PubChem]
Categories: Compounds used in a research, industrial, or household settingCintredekin besudotox
go.drugbank.com/drugs/DB05305InvestigationalCintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual
SSR-126517E
go.drugbank.com/drugs/DB05362ExperimentalSSR-126517E is a second generation synthetic pentasaccharide that binds antithrombin with such high affinity that it assumes a plasma half-life of 80 hours.
Nicaraven
go.drugbank.com/drugs/DB06397ExperimentalCategories: Compounds used in a research, industrial, or household settingGlasdegib
go.drugbank.com/drugs/DB11978ApprovedInvestigational[A40310] Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). … [A258493] Aberrant of Hh signaling is one of the main pathophysiologies of AML, with observed overexpression or constitutive activation of SMO.
MEM 1414
go.drugbank.com/drugs/DB05888ExperimentalMEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. This drug candidate has completed Phase 1 clinical trials.
Lumefantrine co-artemether
go.drugbank.com/drugs/DB13085ApprovedInvestigationalWithdrawnLumefantrine Co-Artemether (Riamet) has been investigated for the treatment of Malaria, Malaria, Falciparum, Malaria in Pregnancy, Uncomplicated Malaria, and Uncomplicated Knowlesi Malaria. … The exact mechanism of action of lumefantrine is not well defined, but it is thought to inhibit -hematin formation, an important detoxification pathway for the parasite.
R450
go.drugbank.com/drugs/DB05469ExperimentalIt is being considered for treatment of stress-related urinary incontinence. … Phase IIa data for the drug show it reduced the number of incontinent episodes compared to placebo with minimal cardiovascular effects.
AER001
go.drugbank.com/drugs/DB05078InvestigationalAER001, an IL4/13 receptor antagonist for severe asthma and eczema currently in Phase 2 studies.
Celivarone
go.drugbank.com/drugs/DB16012InvestigationalCalibrator for the Maintenance of Sinus Rhythm in Patients With Recent Atrial Fibrillation/flutter). … Celivarone is under investigation in clinical trial NCT00233441 (Placebo Controlled Double-blind Dose Ranging Study of the Efficacy and Safety of SSR149744C 50, 100, 200 or 300 Mg OD With Amiodarone as